<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003424</url>
  </required_header>
  <id_info>
    <org_study_id>NMRC-AHCC01</org_study_id>
    <secondary_id>CDR0000066444</secondary_id>
    <secondary_id>EU-98018</secondary_id>
    <nct_id>NCT00003424</nct_id>
  </id_info>
  <brief_title>Tamoxifen in Treating Patients With Primary Liver Cancer</brief_title>
  <official_title>Randomised Trial of Tamoxifen Versus Placebo for the Treatment of Inoperable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Medical Research Council (NMRC), Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen can stimulate the growth of cancer cells. Hormone therapy using tamoxifen
      may fight liver cancer by blocking the absorption of estrogen. It is not yet known whether
      receiving tamoxifen is more effective than no further therapy in treating patients with
      primary liver cancer.

      PURPOSE: Randomized phase III trial to compare high-dose tamoxifen with no further treatment
      in treating patients with liver cancer that cannot be surgically removed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Assess the therapeutic role of tamoxifen in patients with inoperable
      hepatocellular carcinoma in terms of overall survival and quality of life.

      OUTLINE: This is a randomized, double blind, placebo controlled study of tamoxifen. Patients
      are randomized to one of 3 treatment arms. Arm I: Patients receive placebo orally twice daily
      for one year. Arms II and III: Patients receive tamoxifen, at 1 of 2 different doses, orally
      twice daily for one year. Quality of life is assessed before treatment and then monthly
      thereafter. Patients are followed monthly until death.

      PROJECTED ACCRUAL: This study will accrue 300 patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1997</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">June 2000</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Liver Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically or radiologically confirmed inoperable
        hepatocellular carcinoma Serum alfa-feto protein level at least 500 ug/L OR Positive
        lipiodol uptake

        PATIENT CHARACTERISTICS: Age: 10 to 90 Performance status: ECOG 0-3 Life expectancy: Not
        specified Hematopoietic: Not specified Hepatic: Not specified Renal: Creatinine less than
        1.7 mg/dL Other: No encephalopathy

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        chemoembolization therapy for disease No prior systemic chemotherapy for disease Endocrine
        therapy: Not specified Radiotherapy: Not specified Surgery: No prior surgery for disease
        Other: No prior percutaneous injection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierce Chow, MD, PhD, MBBS, FRCS, FAMS</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Centre, Singapore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin, New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Udayana</name>
      <address>
        <city>Sanglah, Denpasar</city>
        <state>Bali</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universiti Kebangsaan Malaysia</name>
      <address>
        <city>Bangi</city>
        <zip>43600</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellington Cancer Centre</name>
      <address>
        <city>Wellington</city>
        <zip>6039</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute - Karachi</name>
      <address>
        <city>Karachi</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nishtar Medical College, Multan</name>
      <address>
        <city>Multan</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tan Tock Seng Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>1130</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre - Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Indonesia</country>
    <country>Malaysia</country>
    <country>New Zealand</country>
    <country>Pakistan</country>
    <country>Singapore</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>August 3, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2004</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

